Eagle Pharma and UPenn collaborating on Alzheimer’s research
15 Jan 2020

Adding to the so far unsuccessful pursuit of trying to find an effective treatment for the devasting condition, Eagle Pharmaceuticals (Nasdaq: EGRX) late Monday announced that Eagle and the University of Pennsylvania (Penn) have agreed on terms of a new exclusive worldwide license agreement for the development of dantrolene sodium for the potential treatment of people living with Alzheimer’s disease, including an agreement to fund additional research and provisions regarding commercialization of products developed under the license.